Key result
Cardiotoxicity trials enrolling ≤26 participants linked to ~96% lower odds of completion.
Cross-Sectional (n=245)
Cardiotoxicity trials on ClinicalTrials.gov face substantial discontinuation and non-publication rates, highlighting the need for mandatory reporting of observational studies and multinational collaboration in interventional trial networks.
Answers are grounded in this paper and cite their sources.
High discontinuation and non-publication rates limit reliable evidence synthesis in cardio-oncology; leaves open identification of modifiable factors to improve trial completion.
Cardiotoxicity from anticancer therapies poses a major clinical challenge, yet the integrity of related clinical trials remains underexplored. We performed a cross-sectional analysis of cardiotoxicity trials registered on ClinicalTrials.gov, identifying 245 eligible studies with 199 completions and 46 discontinuations, of which 82 were published. Observational trials had high completion rates (59/65) yet suffered from profound dissemination failure, with only 13 published. Multicenter design showed a significant independent association with publication (adjusted OR 10.50, 95% CI 1.95-82.00, P = 0.010). In contrast, interventional trials faced greater operational attrition, with Phase II trials exhibiting a particularly high proportion of termination. Notably, trials enrolling ≤ 26 participants were associated with markedly lower odds of completion (adjusted OR 0.04, 95% CI 0.01-0.13, P < 0.001). Among interventional trials, international recruitment was the factor most strongly associated with publication (adjusted OR 3.07, 95% CI 1.27-7.66, P = 0.014). These findings delineate distinct translational barriers across study designs in cardio-oncology. Future priorities should include mandating transparent reporting of completed observational research and strengthening multinational collaboration in interventional trial networks to mitigate discontinuation risk and ensure a robust evidence base for cardiovascular protection.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a cross-sectional in Cardiotoxicity from anticancer therapies (n=245). Trial design and enrollment characteristics (e.g., enrollment ≤ 26 participants, multicenter design, international recruitment) was evaluated on Trial completion (vs. discontinuation) and publication (OR 0.04, 95% CI 0.01-0.13, p=<0.001). Cardiotoxicity trials enrolling ≤26 participants had lower completion odds; overall, 199/245 trials completed and 82/245 were published.
Synapse has enriched 10 related papers. Consider them for comparative context: